Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression.

Both intravenous (IV) ketamine and intranasal esketamine significantly reduce depressive symptoms in adults with treatment-resistant depression (TRD). IV ketamine produced a greater reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS) than esketamine (mean difference about 5 points), especially in highly treatment-resistant patients. Comorbid psychiatric conditions strongly moderated outcomes: patients without comorbidities improved the most (MADRS change -22.0), while those with borderline personality disorder showed minimal response (MADRS change -3.7). Males improved more than females on the MADRS, but no sex difference appeared on the patient-rated PHQ-9. Age had no effect. Personalized approaches considering comorbidity profiles are critical for optimizing outcomes.

Study at a glance

Abstract

Treatment-resistant depression (TRD) poses significant clinical challenges, often necessitating alternative treatments such as intravenous (IV) ketamine or intranasal esketamine. This study compared the effectiveness of these modalities and examined predictors of treatment response, including comorbidity profile, prior antidepressant failures, age, and gender. A retrospective chart review was conducted on 200 adults with TRD treated with IV ketamine (median 6 infusions) or intranasal esketamine (median 8 sessions) at a specialized clinic. Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Patient Health Questionnaire-9 (PHQ-9) at baseline and after acute treatment. Multivariable analyses evaluated the impact of treatment type, psychiatric comorbidities (none, anxiety, PTSD, borderline personality disorder [BPD], multiple), number of failed medications, age, and gender on treatment outcomes. Both treatments significantly reduced depressive symptoms (MADRS mean change: -8.9; PHQ-9: -4, p < 0.0001). IV ketamine produced a greater MADRS reduction than esketamine (mean difference ∼5 points, p = 0.03), especially in highly treatment-resistant patients. Comorbidity profile was a strong moderator: patients without comorbidities experienced the greatest improvement (MADRS -22.0), while those with BPD showed minimal response (MADRS -3.7). Sex had some influence over MADRS outcomes, with males improving more than females (p = 0.03), although no sex difference was evident on the patient-rated PHQ-9 (p = 0.45). Patients age had no effect. IV ketamine may offer superior antidepressant effects compared to esketamine, particularly in patients with severe treatment resistance. However, comorbid psychiatric conditions, especially BPD, attenuate the benefits of both ketamine and esketamine. Personalized approaches considering comorbidity profiles are critical to optimizing outcomes in TRD.